Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel Lanas

Showing results (191-200 of 270) with videos related to

Pageof 27
Sort By:
Frontiers in Pharmacology|March 18, 2024
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug actionPaola Patrignani, Stefania Tacconelli, Annalisa Contursi, et al.
American Heart Journal|September 29, 2014
PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studiesDavid J Whellan, Jay L Goldstein, Byron L Cryer, et al.
Reumatologia Clinica|January 28, 2014
Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)Angel Lanas, Pere Benito, Joaquín Alonso, et al.
Gastroenterology|September 25, 2012
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomasLuis G Carvajal-Carmona, Ann G Zauber, Angela M Jones, et al.
Gastroenterologia Y Hepatologia|February 18, 2014
[Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)]Angel Lanas, Pere Benito, Joaquín Alonso, et al.
Gastroenterology|November 8, 2006
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomasJohn A Baron, Robert S Sandler, Robert S Bresalier, et al.
Nature Reviews. Disease Primers|April 20, 2018
Non-variceal upper gastrointestinal bleedingAngel Lanas, Jean-Marc Dumonceau, Richard H Hunt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 3, 2009
Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessmentEdgardo Smecuol, Maria Ines Pinto Sanchez, Alejandro Suarez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 1, 2006
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin, C Mel Wilcox, Jeroan Allison, et al.
Clinical Therapeutics|March 6, 2012
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placeboNadir Arber, David Lieberman, Timothy C Wang, et al.
Pageof 27

Showing results (191-200 of 270) with videos related to

Sort By:
Pageof 27
Frontiers in Pharmacology|March 18, 2024
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug actionPaola Patrignani, Stefania Tacconelli, Annalisa Contursi, et al.
American Heart Journal|September 29, 2014
PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studiesDavid J Whellan, Jay L Goldstein, Byron L Cryer, et al.
Reumatologia Clinica|January 28, 2014
Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)Angel Lanas, Pere Benito, Joaquín Alonso, et al.
Gastroenterology|September 25, 2012
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomasLuis G Carvajal-Carmona, Ann G Zauber, Angela M Jones, et al.
Gastroenterologia Y Hepatologia|February 18, 2014
[Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)]Angel Lanas, Pere Benito, Joaquín Alonso, et al.
Gastroenterology|November 8, 2006
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomasJohn A Baron, Robert S Sandler, Robert S Bresalier, et al.
Nature Reviews. Disease Primers|April 20, 2018
Non-variceal upper gastrointestinal bleedingAngel Lanas, Jean-Marc Dumonceau, Richard H Hunt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 3, 2009
Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessmentEdgardo Smecuol, Maria Ines Pinto Sanchez, Alejandro Suarez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 1, 2006
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin, C Mel Wilcox, Jeroan Allison, et al.
Clinical Therapeutics|March 6, 2012
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placeboNadir Arber, David Lieberman, Timothy C Wang, et al.
Pageof 27